Professor Judith Trotman (MBChB, FRACP, FRCPA), is Head of Haematology, Concord Repatriation General Hospital, University of Sydney, Australia, Chair of the ALLG Scientific Advisory Committee, where she mentors several Co-PIs in lymphoma trials. She is the Founding Chair and Steering Committee member of Women in Lymphoma (WiL).
Prof Trotman has steered Concord’s leading recruitment of >100 patients to clinical trials of the novel small molecule BTK inhibitors which have improved survival and transformed the quality of life of numerous patients with CLL and other lymphoproliferative diseases. She has several related publications in NEJM, Blood and other leading haematology journals. Through these substantial contributions to clinical research Concord Haematology has become a referral centre for the management of Waldenström Macroglobulinaemia (WM).
Judith is Faculty at the International Workshops WM (IWWM11) and the senior author on the 2023 international WM frontline treatment consensus guidelines. She mentors Dr Ibrahim Tohidi-Esfahani as co-PI on the Waldenström Macroglobulinaemia Study Involving CART-WHEEL (WhiMSICAL), adding scientific rigor to prospectively articulating and amplifying the patient voice for 650 patients with WM. She was awarded the 2022 global Peter S. Bing Humanitarian Award for extraordinary humanitarian service and activism on behalf of patients with WM. Prof Trotman co-chaired the Federal Government Optimal Care Pathway for low grade lymphoma, (2022) and a separate Optimal Care Pathway for Waldenström Macroglobulinaemia (2023).
